Acrodermatitis Continua Suppurativa Of Hallopeau C0392439
A chronic inflammatory skin disease causing painful pustules and skin breakdown, typically on fingers and toes. Can be persistent and difficult to treat. Therapies include topical treatments, immunosuppressants, and biologics.
Key facts at a glance
- ICD-10
- L98.9
- ICD-11
- EA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Topical corticosteroid therapy
High-potency topical corticosteroids as first-line treatment to reduce inflammation, suppress pustule formation, and relieve pain in affected nail folds and fingertips.
Systemic immunosuppressant therapy
Oral immunosuppressants such as methotrexate, cyclosporine, or biologics for moderate to severe cases unresponsive to topical therapy.
Additional treatment options
Nail avulsion and chemical matrixectomy
Surgical removal of affected nail tissue followed by chemical ablation of nail matrix to prevent regrowth in severely affected cases.
procedureAntibiotic therapy for secondary infection
Oral or topical antibiotics targeting Staphylococcal and Streptococcal secondary infections that commonly complicate acrodermatitis continua.
medicationProtective wound care and hand therapy
Specialized wound care protocols combined with hand therapy to maintain function, prevent contractures, and protect sensitive fingertips.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Acrodermatitis Continua Suppurativa Of Hallopeau C0392439?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mrowietz U, et al. European S3-Guidelines on the treatment of acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2022.
Bachmann NM, Koster BD. Acrodermatitis continua of Hallopeau: pathogenesis and treatment update. Dermatol Ther. 2021.
Nellen RG, et al. Biologic therapy for acrodermatitis continua of Hallopeau: a multicenter retrospective analysis. Br J Dermatol. 2020.
Wollina U, Koch A, Hansel G. Acrodermatitis continua of Hallopeau: clinical features and treatment options. Am J Clin Dermatol. 2019.
Medication Comparisons
Compare medications used to treat Acrodermatitis Continua Suppurativa Of Hallopeau C0392439. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy